TY  - BOOK
AU  - Badr, Salem
AU  - Barbash, Israel M
AU  - Ben-Dor, Itsik
AU  - Dvir, Danny
AU  - Laynez-Carnicero, Ana
AU  - Pichard, Augusto D
AU  - Sardi, Gabriel L
AU  - Satler, Lowell F
AU  - Torguson, Rebecca
AU  - Waksman, Ron
TI  - Clinical outcomes after treating acute coronary syndrome patients with a drug-eluting stent: results from REWARDS-EMI (Endeavor for Myocardial Infarction Registry)
SN  - 1878-0938
KW  - *Acute Coronary Syndrome/th [Therapy]
KW  - *Cardiovascular Agents/ad [Administration & Dosage]
KW  - *Drug-Eluting Stents
KW  - *Myocardial Infarction/th [Therapy]
KW  - *Paclitaxel/ad [Administration & Dosage]
KW  - *Percutaneous Coronary Intervention/is [Instrumentation]
KW  - *Sirolimus/aa [Analogs & Derivatives]
KW  - Acute Coronary Syndrome/di [Diagnosis]
KW  - Acute Coronary Syndrome/mo [Mortality]
KW  - Aged
KW  - Coronary Angiography
KW  - Disease-Free Survival
KW  - District of Columbia
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Multivariate Analysis
KW  - Myocardial Infarction/di [Diagnosis]
KW  - Myocardial Infarction/mo [Mortality]
KW  - Percutaneous Coronary Intervention/ae [Adverse Effects]
KW  - Percutaneous Coronary Intervention/mo [Mortality]
KW  - Prospective Studies
KW  - Prosthesis Design
KW  - Registries
KW  - Risk Factors
KW  - Sirolimus/ad [Administration & Dosage]
KW  - Time Factors
KW  - Treatment Outcome
KW  - MedStar Heart & Vascular Institute
KW  - Comparative Study
KW  - Journal Article
KW  - Observational Study
N1  - Available in print through MWHC library: 2002 - present
N2  - BACKGROUND: Drug-eluting stents have shown promising clinical results in the treatment of acute coronary syndrome (ACS) patients. We aimed to evaluate the long-term outcome of Endeavor zotarolimus-eluting stent (EZES) implantation in an ACS population and to compare these results with those obtained in patients treated with sirolimus-eluting (SES) and paclitaxel-eluting stents (PES); CONCLUSION: In an ACS patient population, a lower long-term MACE rate was observed in patients treated with an EZES when compared to treatment with first-generation drug-eluting stents. The use of EZES in contemporary practice has excellent long-term outcome in terms of low rates of revascularization and clinical events. Copyright  2013. Published by Elsevier Inc; METHODS: This prospective study included 1481 consecutive ACS patients (72% myocardial infarction, age 65 + 13 years, 62% male) treated with a drug-eluting stent: (SES, n=925; PES, n=417; EZES, n=139). The primary end point was major adverse cardiac events (MACE) at 2 years, defined as the composite of death, myocardial infarction, and target vessel revascularization. Two-year follow-up was obtained in all patients; RESULTS: Baseline clinical and angiographic characteristics were mostly similar. Unadjusted 2-year MACE and death rates were lower in the EZES group than in the SES and PES groups (MACE: 18.7% vs. 25.3% vs. 30.2%, p=0.02; death: 10.1% vs. 16.4% vs. 22.2%, p=0.002, respectively). The rate of definite stent thrombosis at 2 years was lower in the EZES group without statistically significant difference (0.7% vs. 2.9% SES vs. 1.7% PES, p=0.16). After adjusting for differences in baseline characteristics, EZES use was an independent correlate for 2-year MACE (vs. SES, hazard ratio 0.65, p=0.049; vs. PES, hazard ratio 0.57, p=0.01)
UR  - http://dx.doi.org/10.1016/j.carrev.2013.01.001
ER  -